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Introduction
MicroRNAs play important roles in carcinogenesis and have significant impact on cancer research. Numerous microRNAs have been identified as potential cancer biomarkers and are involved as oncogenes, tumour suppressors as well as regulators of cancer stem cells.
The discovery of microRNA targets and pathways has led to possible applications of microRNA-derived therapeutics in cancers including nasopharyngeal carcinoma (NPC).
NPC is a neoplastic disorder that arises from the lining of the nasopharynx. It is commonly found in geographical areas such as Southern China and South-East Asia, with men: women prevalence ratio of 2-3 to 1. Despite improvements in the management of patients with NPC over the years, it still remained as one of the most difficult malignancies to treat with 80,000 newly diagnosed cases every year and 50,000 annual deaths globally [1] . Its highly invasive nature is continuously being considered as a significant health problem in parts of the world where it is endemic. Hence, there is an urgent need to identify new diagnostic and potential therapeutic targets to help in the management of NPC.
Roles of miRNA in NPC
Over the years, many reports indicated that a high proportion of miRNAs are localised within fragile sites or cancer-associated regions, indicating that miRNAs play a significant role in the pathogenesis of cancer formation [2] [3] [4] [5] [6] . Indeed, many human miRNAs have been reported to alter biological activities such as cell proliferation and progression, apoptosis as well as metastasis in NPC and other cancers [6] [7] [8] [9] . Several biological pathways that are crucial in carcinogenesis showed significant down-regulation of miRNAs [2, 4, 9, 10] .
Despite this, most of these deregulated miRNAs are yet to be fully studied or understood [11] .
Expression levels of miRNAs which were altered in nasopharyngeal carcinoma could potentially be involved in the pathogenesis of NPC by affecting the cell cycles at different levels by targeting different genetic pathways (Table 1) .
miRNAs as tumour suppressor genes
Tumour suppressors function to inhibit cell proliferation, colony formation, migration and invasion in vitro, as well as tumour growth and metastasis in vivo [12] [13] [14] [15] [16] . miR-124 directly targeted Homo sapiens forkhead box Q1(Foxq1) and the level of miR-124 increased with clinical stage and T stage of patients with NPC [12] . In addition, miR-125a-5p increased the expression of p53 and repressed the expression of human epidermal growth factor receptor 2 (Her2) ( Figure 1 ), two important factors in apoptosis [13] . Similarly, miR-31 induced apoptosis by targeting factor inhibiting HIF-1 (FIH1) and MCM2 genes ( Figure 2 ).
Inhibition of FIH1 was able to increase expression of p53 and p21. miR-31 also showed ability to attenuate in vitro anchorage-independent growth and in vivo tumourigenicity [16] .
However, how miR-31 exercised its effect on them is still uncertain.
Similarly, miR-200a and miR-200b acted as tumour suppressors by inhibiting NPC cell growth, migration and invasion via down-regulation of zinc finger E-box binding homeobox 2 (ZEB2; also known as SIP1) and β-catenin (CTNNB1) and Notch1 respectively ( Figure 3 ) [17, 18] . Two studies reported that miR-216b suppressed cell proliferation, invasion and metastasis by inhibiting the expression of protein kinase C alpha (PKCα) and
Kirsten rat sarcoma viral oncogene homolog (KRAS) protein [19, 20] . On the other hand, overexpression of tumour suppressor miR-320a repressed NPC cell growth, migration, invasion and tumour growth in a xenograft mouse model by targeting BMI-1 [15] (Figure 3 ).
In addition, ectopic expression of miR-451 was observed to suppress cell viability, colony formation, and cell migration and invasion by targeting macrophage migration inhibitory factor (MIF) gene ( Figure 3 ) [21] .
miRNAs as oncogenes
Oncogene miR-378 dramatically promoted cell proliferation, colony formation, migration and invasion in vitro, as well as tumour growth in vivo. When miR-378 was overexpressed, it was able to down-regulate the expression of transducer of HER2 (Figure 1 ) [22] . Likewise, tumour promoter miR-141 affected cell cycle, apoptosis, cell growth, migration and invasion in NPC cells by targeting bromodomain containing 3 (BRD3), ubiquitin associated protein 1 (UBAP1) and phosphatase and tensin homolog (PTEN) ( Figure   1 ). BRD3 is involved in the regulation of the Rb/E2F pathway, a pathway which plays an important role in controlling cell growth leading to the induction of DNA replication and S phase in cell cycle [23] whilst PTEN is a crucial tumour suppressor in many tumour types [24, 25] .
Studies revealed that miR-205 also repressed the expression of PTEN and upregulated the expression of protein kinase B (AKT) ( Figure 1 ) [26] . miR-144 shared a similar target as it suppressed the expression of PTEN to increase the expression of AKT and cyclin D1 (CCND1) proteins ( Figure 2 ) to promote G1-phase transition and decreased cell apoptosis [27, 26] . While miR-144 increased expression of CCND1 miR-138 directly targeted CCND1 ( Figure 2 ). It was observed that overexpression of miR-138 lead to inhibition of cell growth and cell cycle progression in NPC cells [14] .
In several scenarios, miRNAs that were able to inhibit certain target genes were in turn inhibited by the same gene targeted, showing a complex negative feedback mechanism.
For example, miR-18b down-regulated connective tissue growth factor (CCN2 or CTGF)
which subsequently lead to enhanced proliferation in vitro and in vivo via PI3K-AKT-C-Jun and C-Myc pathway ( Figure 1 ). However, overexpression of CTGF in turn repressed the expression of miR-18b via PI3K-AKT-C-Jun and C-Myc pathway [21] .
2.3
Roles of miRNA in cell cycle progression
Because any mutation towards cell cycle could possibly lead to uncontrolled proliferation, studies have also focused on miRNAs effect on cell cycle analysis. For example, miR-663 targeted p21WAF1/CIP1 to promote cellular G1/S transition leading to increased proliferation of NPC cells [28] . Similarly, by down-regulating multiple G1/S related cyclin/CDK/Rb/E2F signalling pathway, miR-188 was able to inhibit cell proliferation, tumour colony formation and G1/S cell cycle transition [29] .
Tumour suppressor miR-26a inhibited cell proliferation and colony formation by . miR-26a was also found to hamper migratory and invasive capacities of NPC cells in vitro and hindered metastatic behaviour of NPC cells in vivo possibly through the action of suppressing enhancer of zeste homolog 2 (EZH2) [31, 32] .
A similar role was observed in miR-98 and miR-101 which attenuated EZH2 expression [32] ( Figure 4 ). This study showed that it is possible for multiple miRNAs to influence a single gene target.
Although knowledge on specific roles of miRNAs in NPC are still lacking, evidences strongly suggest that miRNAs can either act as oncogenes (miR-93, miR-149 and miR-214) and/or tumour suppressors (miR-100, miR-143, miR-148a and Let-7) by regulating several biological processes including cell proliferation, migration, invasion and metastasis [33] [34] [35] [36] [37] [38] [39] ( Table 2 ). In addition, the varsity of miRNAs, their multiple targets and their effects on various pathways show an extreme intricate web of connections in their ability to affect NPC progression ( Figure 5 ).
miRNA implicated in EBV positive NPC
Latent membrane protein 1
Studies have shown that the aetiology of NPC is multifactorial, taking into account environmental factors, Epstein-Barr virus (EBV) infection, age and genetic background.
However, it is unclear why certain individual with all the risk factors never develop NPC, whilst others who have no apparent risk factors do. Recently, an increasing amount of data has shown that EBV was able to regulate certain miRNAs which lead to NPC progression and invasion. EBV-encoded latent membrane protein one (LMP1) is one of the recognised oncogene that has been well studied and documented in the pathogenesis of NPC [8, 40] .
LMP1 simulates CD40 receptor and activate multiple cell signalling pathways such as inhibitor of differentiation, nuclear factor-κB (NF-κB), activator protein-1 (AP-1), signal transducers and activators of transcription (STAT), and tumour necrosis factor receptorassociated factors (TRAFs). Up-regulation of miR-146a by LMP1 suggested the possible oncogenic implication of miR-146a in the pathogenesis of NPC [41] . Additionally, increased LMP1 copies in NPC cell lines was correlated with an increase in miR-155 which stimulated NPC cell proliferation, colony formation, cell migration and invasion [42] . However, no studies were done on how miR-155 was able to exhibit its oncogene effect in NPC. Similarly, miR-10b was overexpressed in LMP1 expressing cell lines [33] and it in-turn up-regulated Ecadherin and enhanced the expression of matrix metallopeptidase 9 (MMP-9) ( Figure 4) signifying the importance of miRNA in cancer invasion and metastasis [43] .
Whilst some miRNAs stimulated NPC progression, others functioned as tumour suppressors. miR-203 was able to attenuate EBV-induced S-phase entry and transformation in vivo leading to suppression of NPC cell growth [44] . Also, mir-204 was able to inhibit EBV positive C666-1 cell invasion and metastasis partly through targeting cdc42 [45] .
BART miRNA
Incredibly, EBV was able to produce its own miRNA called the BART miRNAs and BHRF1 miRNAs. They are encoded by two sets of transcripts, with one from the BART region and the other near the BHRF1 cluster. BART miRNAs and BHRF1 miRNAs were first identified as abundant viral transcripts generated from NPC in the early nineteen nineties [46, 47] . In usual miRNA biogenesis, one strand of the miRNA hairpins is selected to be the mature miRNA whilst the other strand is degraded [48] . However, both strands of the BART miRNA original hairpin can often persist and be functionally relevant [49] . To distinguish between these two potential miRNAs, the suffixes "-5p" and "-3p" have been used to designate the 5' end of the hairpin and 3' end of the hairpin [50] . Nowadays, BART gene accounts for 22 miRNA precursors which produces 44 mature BART miRNAs which are all suggested to be implicated in the pathogenesis of NPC [51] .
The expression profile of EBV miRNAs has been comprehensively studied in NPC.
Multiple reports confirmed the abundant expression of the BART miRNAs in NPC tissues in the absence of BHRF1 miRNAs. A recent study revealed that all 44 BART miRNAs were expressed in NPC tumours, at broadly similar levels [52] . Interestingly, approximately onesixth of the total miRNA content in NPC cells attributed to BART miRNAs, suggesting that BART miRNAs provided a considerable portion of the total regulatory influence of both viral and cellular genes in NPC tumour cells [53] . Edwards and colleagues established that the expression of these BART miRNAs was the highest in stage III but reduced in stage IV NPC samples, and were not noted in non-cancer biopsies and EBV-negative cell lines [54] .
Several BART miRNAs have been subjected to further experiments and were shown to be implicated in the pathogenesis of NPC with their targets suggested or identified.
Apoptosis was triggered by depleting miR-BART5 or inducing the expression of p53 upregulated modulator of apoptosis (PUMA) ( Figure 6 ) in NPC cells [55] , which is a proapoptotic member of the B-cell lymphoma 2 (BCL-2) protein family [56] . PUMA is involved in p53 dependent and independent apoptosis induced by a variety of signals which after activation, interacts with anti-apoptotic BCL-2 family members BAX and BAK to signal apoptosis to the mitochondria. Following mitochondrial dysfunction, the caspase cascade is activated ultimately leading to cell death [57] .
On the other hand, phosphoglycerate dehydrogenase (PHGDH) expression levels were significantly up-regulated in the presence of high levels of miR-BART1 in NPC specimens. PHGDH diverted glucose-derived carbon into a specific biosynthetic pathway, contributing to carcinogenesis [58] . Another report showed that deleted in cancer 1 (DICE1), a tumour suppressor, was the cellular target of EBV miR-BART3 miRNA and expression of miR-BART3 overpowered the growth suppressive activity of DICE1 and stimulated cell proliferation [59] .
Studies have reported that plasma miR-BART7 and miR-BART13 levels were significantly higher in patients with NPC when compared to healthy individuals. Their expressions enhanced proliferation, migration, and invasion of NPC cells and conferred tumour resistance to cisplatin [60, 61] . The expression of miR-BART7 in NPC cells caused a large-scaled aberrant gene expressions, with genes related to the calcium signalling pathway being affected the most (p=0.003) [60] . It is worth noting that calcium signalling pathway has been implicated in the pathogenesis of several malignancies [62] [63] [64] .
miR-BART9 was observed to target E-cadherin which enhanced migratory ability and invasiveness of NPC cells contributing to the aggressiveness of tumour cells [65] . It was also reported that miR-BART22 targeted mitogen-activated protein kinase kinase kinase 5 (MAP3K5) and LMP2A, inhibiting NPC cell apoptosis and, preventing their differentiation as well as permitting escape of EBV-infected cells from host immune surveillance [66, 67] .
Combining miRNA Treatment with Current NPC Treatments
Long and colleagues showed that hypo-fractionated radiotherapy increased the expression of miR-34a, and stimulated p53 promoter activity and down-regulated the expression of c-Myc protein in NPC cells. When miR-34a was suppressed, hypo-fractionated radiotherapy seemed less effective in inhibiting NPC cell growth [68] . Their findings suggested that the effectiveness of current treatment of NPC may be a result of their modulation in miRNA expressions. Future therapy could place more emphasis in identifying potential miRNAs as molecular targeted therapy which could have fewer side effects in comparison with current NPC treatments. Undeniably, the combination of current chemotherapeutic drugs for NPC with miRNA has produced some promising results. miR-1 was shown to induce earlier apoptosis via targeting prothymosin alpha, ProTalpha (PTMA) when combined with chemotherapeutic agents such as actinomycin D, camptothecin and etoposide [69] . Similarly, miR-29c which showed anti-metastasis property by targeting T cell lymphoma invasion and metastasis 1 (TIAM1) gene [70] (Figure 4 ) was found to sensitise NPC cells to ionizing radiation and cisplatin treatment via inhibition of anti-apoptotic factors myeloid cell leukaemia 1 (MCL-1) and BCL-2 (Figure 3 ), promoting apoptosis [31] . These evidences have opened up a new gateway of research to identify potential therapeutic targets for NPC.
miRNA as New Therapeutic Targets in NPC
In view of the few strikingly altered differential miRNA expressions in NPC, the activation of tumour-suppressive miRNAs and/or inhibition of oncogenic miRNAs may have the potential to provide a fundamentally new approach for the development of therapeutics for NPC. Probably the most important advantage of miRNA gene therapy in comparison with current approaches of targeting single genes is its ability to modulate many different pathways or targets all at once, thus improving its effectiveness greatly [71] . Table 4 shows a summary on current evidences of miRNAs affected during radiotherapy. It is hoped that manipulating these miRNAs (miR-7, miR-23a, miR-29c, miR-205 and miR-451) could give similar anti-cancer effects towards NPC as radiotherapy but with less adverse side effects.
miRNA as diagnostic and prognostic biomarker in NPC
The main hindrance in combating NPC is the difficulty in early detection and accurate prognosis of the disease. This is partly a result of inadequate knowledge in the molecular pathogenesis of NPC. In addition, the lack of effective biomarkers and poor response to current therapies accounts for the large proportion of NPC patients (~70 %) being diagnosed at later stages [72] [73] [74] . An in-depth understanding of miRNA expression profiles might help identify potential reliable and robust biomarkers for early NPC detection. In the recent years, a number of miRNAs have been identified as potential diagnostic and prognostic markers in NPC ( 
Conclusion
Undoubtedly, the greatest challenge faced in application of miRNA biology in the clinical management of patients with NPC is the identification of the genes that each miRNA targets as reported in many cases.
Future miRNA investigation may focus on further elucidating the function of the miRNAs in this review. For example, miR-1 which shown positivity as an apoptotic miRNA can be tested on its efficiency as a therapeutic drug. On the other hand, a number of studies have been focusing on miR-29c. This tumour suppressor miRNA was targeted as a potential biomarker and studied for its anti-metastatic as well as pro-apoptotic effects towards NPC.
However, studies on its effect towards laminin and collagen (often associated with solid tumour metastasis) have only been proven via bioinformatics studies. Future investigations may focus on identifying if miR-29c indeed target genes. In addition, it would also be interesting to find out the target gene(s) of miR-31 that reduces in vitro anchorageindependent growth and in vivo tumourigenicity of NPC.
Overall, further validations should be done on the miRNAs that are potentially useful for the diagnosis, prognosis or assessment of sensitivity to radiotherapy or chemotherapy in patients with nasopharyngeal carcinoma. New gene targeting therapies may be found when the targeting genes of the miRNAs are identified and studied.
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Overexpression of miR-143 causes a significant reduction of the adhesion ability by targeting GLI3 Li/2013 [35] miR-148a Inhibit cell migration in NPC cells by targeting VAV2, WASL and ROCK1 Wong/2011 [36] Let-7
Inhibit NPC cell proliferation by repressing cmyc Oncogene Lyu/2014 [37] miR-93 Down-regulate transforming growth factor-β receptor II (TGFβR2) and causing attenuation of Smad-dependent TGF-β signalling and the activation of PI3K/Akt pathway which led to cell proliferation, invasion and metastasis of NPC Luo/2011 [38] miR-149
Promote proliferation of NPC cell lines by increasing E-cadherin Deng/2013 [39] miR-214
Mimics significantly repressed lactotransferrin (LTF) mRNA and protein levels in NPC cells to promote NPC cell proliferation and invasion in addition to hastening tumour formation and lung metastasis in mouse xenografts. Significantly decreased level of miR-9 in patients with NPC was confirmed through two-stage validation. Low level of plasma miR-9 was significantly correlated with lymphatic invasion and advanced TNM stage. The plasma miR-9 level was significantly elevated in post-treatment plasma compared with those pre-treatment samples. Zeng/2012 [78] miR-17 miR-20a miR-29c miR-223
Microarray-based serum miRNA profiling on the serum of twenty nasopharyngeal carcinoma patients at diagnosis along with 20 non-cancerous individuals as controls was carried out in which miR-17, miR-20a, miR-29c, and miR-223 were found to be expressed differentially in the serum of patients with NPC compared with those of non-cancerous control. Liu Y/2014 [13] miR-125a-5p
Functioned as a regulator and predictor of effect of gefitinib's on NPC Liu Y/2013 [79] miR-151 CCNE1's polymorphisms located at miRNA-151 binding sites are associated with NPC susceptibility and are correlated with pathological stages of NPC. Du/2011 [80] miR-155
Driven by LMP1 and LMP2A and down-regulated JMJD1A. Down-regulation of JMJDA was significantly correlated with advanced N stage, a lower five-year survival rare and a lower five-year disease-free survival rate in patients with NPC. Ma/2014 [45] 
miR-204
Low-level expression of miR-204 was significantly associated with a more aggressive and poor prognostic phenotype of NPC. Deng/2013 [19] miR-216b
Decreased expression of miR-216b was directly related to advanced clinical stage and lymph node metastasis whilst miR-216b levels correlated inversely with levels of KRAS protein during nasopharyngeal carcinogenesis Li/2013 [81] miRNA-324-3p
Down-regulation of miRNA-324-3p and up-regulation of WNT2B were significantly correlated with advanced clinical stages of NPC Liu/2013 [82] miR-451 miR-451 was significantly down-regulated in NPC cell lines and clinical tissues (P < 0.01) and patients with low expression of miR-451 had poorer overall survival and disease-free survival. Zheng/2014 [83] miR-483-5p miR-548q
Most patients with NPC with poor outcome exhibited high expression of miR-548q (70.6%) and miR-483-5p (64.7%) in tissue samples, indicating their prognostic value. 
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